EA201391797A1 - 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS - Google Patents

3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS

Info

Publication number
EA201391797A1
EA201391797A1 EA201391797A EA201391797A EA201391797A1 EA 201391797 A1 EA201391797 A1 EA 201391797A1 EA 201391797 A EA201391797 A EA 201391797A EA 201391797 A EA201391797 A EA 201391797A EA 201391797 A1 EA201391797 A1 EA 201391797A1
Authority
EA
Eurasian Patent Office
Prior art keywords
derivatives
greeline
agonists
receptors
piperidine derivatives
Prior art date
Application number
EA201391797A
Other languages
Russian (ru)
Inventor
Амит Виджай Амбаркхане
Гурдип Бхалай
Мартин Бекетт
Джеймс Дэйл
Ахмед Хамади
Алессандро Маццакани
Джеффри МакКенна
Кристофер Томсон
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46317469&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201391797(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of EA201391797A1 publication Critical patent/EA201391797A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретение относится к производным формулы (I), где заместители представляют собой, как определено в описании; к способам получения данных производных; фармацевтическим композициям, содержащим данные производные; данным производным в качестве лекарственного средства; данным производным для лечения расстройства или заболевания, опосредованного грелиновым рецептором.The invention relates to derivatives of formula (I), where the substituents are, as defined in the description; to methods for obtaining these derivatives; pharmaceutical compositions containing these derivatives; given derivatives as a medicine; derivatives for the treatment of a disorder or disease mediated by a ghrelin receptor.

EA201391797A 2011-05-27 2012-05-25 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS EA201391797A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161490848P 2011-05-27 2011-05-27
US201161560960P 2011-11-17 2011-11-17
US201261642116P 2012-05-03 2012-05-03
PCT/IB2012/052649 WO2012164473A1 (en) 2011-05-27 2012-05-25 3-spirocyclic piperidine derivatives as ghrelin receptor agonists

Publications (1)

Publication Number Publication Date
EA201391797A1 true EA201391797A1 (en) 2014-04-30

Family

ID=46317469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391797A EA201391797A1 (en) 2011-05-27 2012-05-25 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS

Country Status (21)

Country Link
US (2) US8546416B2 (en)
EP (1) EP2714690A1 (en)
JP (1) JP2014515369A (en)
KR (1) KR20140023399A (en)
CN (1) CN103562206A (en)
AP (1) AP2013007234A0 (en)
AR (1) AR086554A1 (en)
AU (1) AU2012264305A1 (en)
BR (1) BR112013030391A2 (en)
CA (1) CA2835916A1 (en)
CL (1) CL2013003211A1 (en)
CO (1) CO6811856A2 (en)
CR (1) CR20130625A (en)
EA (1) EA201391797A1 (en)
IL (1) IL229320A0 (en)
MX (1) MX355072B (en)
PE (1) PE20140610A1 (en)
SG (1) SG194616A1 (en)
TW (1) TW201302749A (en)
UY (1) UY34094A (en)
WO (1) WO2012164473A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201348235A (en) * 2012-05-03 2013-12-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
ES2689906T3 (en) * 2012-08-09 2018-11-16 Dynamis Therapeutics, Inc. Meglumine to reduce high triglyceride levels
CU24442B1 (en) * 2014-04-04 2019-09-04 X Rx Inc DERIVATIVES OF N- (1- (SPIROCYCLIC) OXO) AMIDE REPLACED AS AUTOTAXIN INHIBITORS
TW201625613A (en) * 2014-10-31 2016-07-16 拉夸里亞創藥股份有限公司 Tetrahydropyrazolopyridine derivatives as ghrelin receptor agonists
EP3621618A4 (en) * 2017-05-12 2021-01-27 Millennium Pharmaceuticals, Inc. Treatment of gastroparesis with triazaspiro(4.5)decanone
CN111175387B (en) * 2018-11-13 2022-06-07 成都康弘药业集团股份有限公司 Method for detecting milnacipran isomer
CN113125583B (en) * 2019-12-30 2022-06-21 成都百裕制药股份有限公司 Method for detecting content of genotoxic impurities in pantoprazole sodium for injection
US11993600B2 (en) * 2021-12-08 2024-05-28 Enanta Pharmaceuticals, Inc. Saturated spirocyclics as antiviral agents

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT72076A (en) * 1992-12-11 1996-03-28 Merck & Co Inc Process for preparing spiro piperidines and homologs which promote release of growth hormone and pharmaceutical compositions containing them
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
CA2220055C (en) 1995-05-08 2001-04-24 Pfizer Inc. Dipeptides which promote release of growth hormone
US6403599B1 (en) 1995-11-08 2002-06-11 Pfizer Inc Corticotropin releasing factor antagonists
AU7169696A (en) * 1995-09-26 1997-04-17 Merck & Co., Inc. 3-spirolactam, 3-spiroamino, 3-spirolactone and 3-spirobenzopyran piperidines and pyrrolidines promote release of growth hormone
AU3220097A (en) 1996-05-22 1997-12-09 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
JP3514774B2 (en) 1997-06-25 2004-03-31 ファイザー・インク Dipeptide derivatives as growth hormone secretagogues
UA64751C2 (en) 1997-06-25 2004-03-15 Пфайзер Продактс Інк. Treatment of insulin tolerance using substances increasing growth hormone secretion
TW544448B (en) 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
ZA987385B (en) 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6329342B1 (en) 1997-08-19 2001-12-11 Eli Lilly And Company Treatment of congestive heart failure with growth hormone secretagogues
GB9802251D0 (en) 1998-02-03 1998-04-01 Ciba Geigy Ag Organic compounds
EP1117403B1 (en) 1998-10-02 2003-12-10 Novartis AG Mglur5 antagonists for the treatment of pain and anxiety
US6194578B1 (en) 1998-11-20 2001-02-27 Pfizer Inc. Dipeptide derivatives
EP1486498A1 (en) 1998-11-23 2004-12-15 Pfizer Products Inc. Process and intermediates for growth hormone secretagogues
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
DOP2001000154A (en) 2000-05-25 2002-05-15 Pfizer Prod Inc COMBINATION OF SECRETAGOGOS OF HORMONE OF THE GROWTH AND ANTIDEPRESSANTS
DE60140285D1 (en) 2000-05-31 2009-12-10 Pfizer Prod Inc Use of growth hormone secretagogues to promote the mobility of the digestive tract
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
GB0028702D0 (en) 2000-11-24 2001-01-10 Novartis Ag Organic compounds
IL157815A0 (en) 2001-03-26 2004-03-28 Novartis Ag Fused pyridine derivatives for use as vanilloid receptor antagonists for treating pain
PT1389183E (en) 2001-05-14 2010-04-26 Novartis Ag Sulfonamide derivatives
JP3894035B2 (en) 2001-07-04 2007-03-14 東レ株式会社 Carbon fiber reinforced substrate, preform and composite material comprising the same
TW200306839A (en) 2002-02-06 2003-12-01 Novartis Ag Quinazolinone derivatives and their use as CB agonists
AU2003218273A1 (en) 2002-04-10 2003-10-27 Eli Lilly And Company Stereoselective process for the synthesis of (d)-2-amino-5-phenylpentanoic or alkyl ester thereof
US6696468B2 (en) 2002-05-16 2004-02-24 Dainippon Pharmaceutical Co., Ltd. (s)-4-amino-5-chloro-2-methoxy-n-[1-[1-(2-tetrahydrofuryl-carbonyl)-4-piperidinylmethyl]-4-piperidinyl]benzamide, process for the preparation thereof, pharmaceutical composition containing the same, and intermediate therefor
SE0201940D0 (en) 2002-06-20 2002-06-20 Astrazeneca Ab New combination II
DOP2003000703A (en) 2002-09-20 2004-03-31 Pfizer IMIDAZOPIRADINE COMPOUNDS AS 5-HT4 RECEIVER AGONISTS
GB0223730D0 (en) 2002-10-11 2002-11-20 Novartis Ag Organic compounds
AR042206A1 (en) 2002-11-26 2005-06-15 Novartis Ag PHENYLACETIC ACIDS AND DERIVATIVES
GB0302876D0 (en) 2003-02-07 2003-03-12 Novartis Ag Organic compounds
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2004277319A (en) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd 1-(4-piperidinylmethyl)piperidinylamide derivative and medicinal composition containing the same
JP2004277318A (en) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd 1-(1-substituted carbonyl-4-piperidinylmethyl)piperidine derivative and medicinal composition containing the same
UA84146C2 (en) 2003-05-21 2008-09-25 Прозидион Лимитед Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents
EP1505064A1 (en) 2003-08-05 2005-02-09 Bayer HealthCare AG 2-Aminopyrimidine derivatives
EP1656145A1 (en) 2003-08-12 2006-05-17 F. Hoffmann-La Roche Ag Spiro-substituted tetrahydroquinazolines as corticotropin releasing factor (cfr) antagonists
DE602004009200T2 (en) 2003-08-12 2008-07-10 F. Hoffmann-La Roche Ag TETRAHYDROCHINAZOLINE DERIVATIVES AS CFR ANTAGONISTS
WO2005068448A1 (en) 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides antagonising n-type calcium channels
EP1675858A2 (en) 2003-09-03 2006-07-05 Neurogen Corporation 5-aryl-pyrazolo [4,3-d] pyrimidines, pyridines, and pyrazines and related compounds
CA2537127C (en) 2003-09-03 2011-04-05 Pfizer Inc. Benzimidazolone compounds having 5-ht4 receptor agonistic activity
JP2005082508A (en) 2003-09-05 2005-03-31 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogeno-n-(1-substituted-4-piperidinyl)pyridine-3-carboxamide derivative and pharmaceutical composition containing the same
JP2007504271A (en) 2003-09-05 2007-03-01 ニューロジェン・コーポレーション Heteroaryl-fused pyridines, pyrazines and pyrimidines which are CRF1 receptor ligands
EP1666468A4 (en) 2003-09-09 2007-03-21 Ono Pharmaceutical Co Crf antagonists and heterobicyclic compounds
GB0322612D0 (en) 2003-09-26 2003-10-29 Novartis Ag Organic compounds
US20050070527A1 (en) 2003-09-30 2005-03-31 Edwards James P. Quinoxaline compounds
JP2005104896A (en) 2003-09-30 2005-04-21 Dainippon Pharmaceut Co Ltd 2-alkoxy-6-amino-5-halogenopyridine-3-carboxamide derivative and pharmaceutical composition containing the same
RU2006110561A (en) 2003-09-30 2007-10-10 Янссен Фармацевтика Н.В. (Be) COMPOUNDS OF BENZOIMIDAZOLE
WO2005044793A2 (en) 2003-10-31 2005-05-19 Takeda Pharmaceutical Company Limited Nitrogen-containing fused heterocyclic compounds
CA2545254A1 (en) 2003-11-10 2005-05-26 Merck & Co., Inc. Substituted triazoles as sodium channel blockers
US7208596B2 (en) 2003-11-25 2007-04-24 Bristol-Myers Squibb Pharma Company Processes for the preparation of pyrazolo[1,5-a]-1,3,5-triazines and intermediates thereof
WO2005054239A1 (en) 2003-12-05 2005-06-16 Bayer Healthcare Ag 2-aminopyrimidine derivatives
US7211568B2 (en) 2003-12-18 2007-05-01 Kosan Biosciences Incorporated 9-Desoxoerythromycin compounds as prokinetic agents
JP2005206590A (en) 2003-12-25 2005-08-04 Mitsubishi Pharma Corp Selective inhibitor of sodium channel site 2
CA2551686C (en) 2004-01-07 2014-09-23 Ian Irwin Stereoisomeric compounds and methods for the treatment of gastrointestinal and central nervous system disorders
WO2005073222A1 (en) 2004-01-29 2005-08-11 Pfizer Japan, Inc. 1-isopropyl-2-oxo-1,2-dihydropyridine-3-carboxamide derivatives having 5-ht4 receptor agonistic activity
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
WO2005092882A1 (en) 2004-03-01 2005-10-06 Pfizer Japan, Inc. 4-amino-5-halogeno-benzamide derivatives as 5-ht4 receptor agonists for the treatment of gastrointestinal, cns, neurological and cardiovascular disorders
EP1574478A1 (en) 2004-03-08 2005-09-14 Solvay Fluor GmbH Preparation of carbonyl difluoride
BRPI0509164A (en) 2004-03-25 2007-09-11 Janssen Pharmaceutica Nv imidazole compounds
AU2005231332A1 (en) 2004-03-29 2005-10-20 Merck & Co., Inc. Biaryl substituted pyrazinones as sodium channel blockers
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
EP1734820A4 (en) 2004-04-16 2008-01-23 Neurogen Corp Imidazopyrazines, imidazopyridines, and imidazopyrimidines as crf1 receptor ligands
GB0412769D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
GB0412768D0 (en) 2004-06-08 2004-07-07 Novartis Ag Organic compounds
KR100875558B1 (en) 2004-06-15 2008-12-23 화이자 인코포레이티드 Benzimidazolone Carboxylic Acid Derivatives
SE0401653D0 (en) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
WO2006023757A2 (en) 2004-08-19 2006-03-02 University Of Virginia Patent Foundation Novel tricyclic, bicyclic, monocyclic, and acyclic amines as potent sodium channel blocking agents
GB0420424D0 (en) 2004-09-14 2004-10-20 Ionix Pharmaceuticals Ltd Therapeutic compounds
WO2006038594A1 (en) 2004-10-04 2006-04-13 Ono Pharmaceutical Co., Ltd. N-type calcium channel inhibitor
GB0519957D0 (en) 2005-09-30 2005-11-09 Sb Pharmco Inc Chemical compound
US7396933B2 (en) 2004-11-05 2008-07-08 Theravance, Inc. Quinolinone-carboxamide compounds
DE602005016446D1 (en) 2004-11-05 2009-10-15 Theravance Inc 5-HT4 receptor agonist compounds
US20080269239A1 (en) 2004-11-11 2008-10-30 Argenta Discovery Ltd. Pyrimidine Compounds as Histamine Modulators
US20060111416A1 (en) 2004-11-24 2006-05-25 Lane Charlotte A L Octahydropyrrolo[3,4-C]pyrrole derivatives
KR20070091665A (en) 2004-12-22 2007-09-11 세라밴스 인코포레이티드 Indazole-carboxamide compounds
EP1818061A1 (en) 2005-12-02 2007-08-15 Charite-Universitätsmedizin Berlin Use of ghrelin for stimulating hair growth
US7601844B2 (en) 2006-01-27 2009-10-13 Bristol-Myers Squibb Company Piperidinyl derivatives as modulators of chemokine receptor activity
EA200901077A1 (en) 2007-02-09 2010-04-30 Транзим Фарма, Инк. MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION
US7994203B2 (en) 2008-08-06 2011-08-09 Novartis Ag Organic compounds
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
EP2482813A4 (en) 2009-09-30 2013-02-27 Tranzyme Pharma Inc Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same

Also Published As

Publication number Publication date
BR112013030391A2 (en) 2016-12-13
KR20140023399A (en) 2014-02-26
CL2013003211A1 (en) 2014-07-04
UY34094A (en) 2013-01-03
CA2835916A1 (en) 2012-12-06
PE20140610A1 (en) 2014-05-31
CN103562206A (en) 2014-02-05
TW201302749A (en) 2013-01-16
WO2012164473A1 (en) 2012-12-06
AR086554A1 (en) 2014-01-08
AP2013007234A0 (en) 2013-11-30
MX355072B (en) 2018-04-04
MX2013013950A (en) 2014-01-23
JP2014515369A (en) 2014-06-30
CO6811856A2 (en) 2013-12-16
CR20130625A (en) 2014-02-04
US20120302540A1 (en) 2012-11-29
US20130331369A1 (en) 2013-12-12
EP2714690A1 (en) 2014-04-09
IL229320A0 (en) 2014-01-30
AU2012264305A1 (en) 2013-11-21
SG194616A1 (en) 2013-12-30
US8546416B2 (en) 2013-10-01

Similar Documents

Publication Publication Date Title
EA201390381A1 (en) TRIAZINOXADIAZOLES
EA201391797A1 (en) 3-SPIROCYCLIC PIPERIDINE DERIVATIVES AS AGONISTS OF GREELINE RECEPTORS
CY1118379T1 (en) DISEASES OF USVITIS C
EA201591087A1 (en) NEW BENZIMIDAZOLE DERIVATIVES AS ANTAGONISTS OF EP4 RECEPTOR
EA201501122A8 (en) NEW AGONISTS OF SOMATOSTATIN RECEPTORS OF SUB-TYPE 4 (SSTR4)
EA201290940A1 (en) NEW CONNECTIONS AS SELECTIVE ANTAGONISTS OF NK3 RECEPTOR, PHARMACEUTICAL COMPOSITION AND METHODS OF THEIR USE FOR DAMAGE MEDIATED BY NK3 RECEPTORS
EA201591195A1 (en) NEW QUINOLON DERIVATIVES
CY1116328T1 (en) Derivative 4 - aminopyrimidine and their use as adenosine A2A receptor antagonists
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
NI201400043A (en) 4 - PHENYL - PYRIDINES SUBSTITUTED FOR THE TREATMENT OF DISEASES RELATED TO THE NK1 RECEPTOR
EA201390969A1 (en) GLUCAGON RECEPTOR MODULATORS
EA201500298A1 (en) ALCOXYPHAZOLES AS ACTIVATORS OF SOLUBLE GUANYLATZYCLASES
CY1123456T1 (en) METHOD OF PREPARATION OF OPTICALLY PURE AND OPTIONALLY SUBSTITUTED 2-(1-HYDROXY-ALKYL)-CHROME-4-ONE DERIVATIVES AND THEIR USE IN THE PREPARATION OF PHARMACEUTICAL SUBSTANCES
EA201492287A1 (en) DEUTERED DERIVATIVES RUXOLITINIBA
EA201492023A1 (en) REGULATORS OF THE COMPLEX WAY AND THEIR APPLICATION
EA201200471A1 (en) SIMPLE ESSENTIAL DERIVATIVES OF BICYCLIC HETEROARILS
MX2016007128A (en) Ccr6 compounds.
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
EA201300946A1 (en) ASYMMETRIC UREA AND THEIR MEDICAL APPLICATION
EA201391056A1 (en) Heteroaryl compounds as ligands of the 5-HTRECEPTOR
MX360330B (en) Administration regime for nitrocatechols.
CY1116720T1 (en) 2-AMINO-3- (IMIDAZOL-2-YL) -PYRIDIN-4-ONE PRODUCER AND THEIR USE AS VEGF RECEPTOR MODEL INSPECTORS
MX339858B (en) Novel compounds as histamine h3 receptor ligands.
EA201270302A1 (en) ANHARROUND FORMS OF PYRIDINE DERIVATIVES
CR20130318A (en) NEW BENZODIOXOL-PIPERAZINA COMPOUNDS